- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety ; volume:16 ; number:1 ; day:27 ; month:7 ; year:2023 ; pages:1-14 ; date:12.2023
Journal of hematology & oncology ; 16, Heft 1 (27.7.2023), 1-14, 12.2023
- Creator
-
Verstovsek, Srdan
Mesa, Ruben A.
Livingston, Robert A.
Hu, Wilson
Mascarenhas, John
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-023-01471-z
- URN
-
urn:nbn:de:101:1-2023103012372678242450
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Verstovsek, Srdan
- Mesa, Ruben A.
- Livingston, Robert A.
- Hu, Wilson
- Mascarenhas, John
- SpringerLink (Online service)
Other Objects (12)
Management of myelofibrosis after ruxolitinib failure
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Management of myelofibrosis after ruxolitinib failure
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Management of myelofibrosis after ruxolitinib failure
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes